Eksigent Technologies, a leading provider of advanced low-flow fluid delivery technologies for drug discovery and other life science applications, will increase manufacturing capacity by 40 percent to meet strong demand for its HPLC products.
“The need for this increase in product build capability is being driven by higher than expected customer demand for both our cHiPLC-nanoflex for proteomics, introduced in February of this year, and our ExpressHT-Ultra HPLC System for ADME-Tox and DMPK studies, introduced last fall,” stated David Neyer, vice president and co-founder of Eksigent. “We are also actively recruiting for field service personnel to ensure that customer installations are maintained at our traditionally short lead times.”
Eksigent’s Board of Directors approved spending last month for additional equipment, tools and staff. “Fortunately, the plant space was available to immediately accommodate this expansion, which will be complete next month,” said Wade Guindy, Eksigent vice president of R&D, engineering and operations.
The new cHiPLC-nanoflex System is a docking station for up to three microfluidic chips that contain nanoLC or trap columns. The system delivers improved reproducibility and ease of use to proteomics research. The ExpressHT-Ultra HPLC system is the latest offering in Eksigent’s line of products for small molecule analysis. It provides short cycle times and high throughput for LC/MS studies of pharmacokinetics and drug metabolism.
Date: July 21, 2009
Source: Eksigent Technologies
Filed Under: Drug Discovery
